These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 24196916

  • 1. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
    Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F.
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
    [Abstract] [Full Text] [Related]

  • 2. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
    Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espié M.
    J Natl Cancer Inst; 2012 Dec 19; 104(24):1879-87. PubMed ID: 23243198
    [Abstract] [Full Text] [Related]

  • 3. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Cancer; 2015 Nov 15; 121(22):3965-74. PubMed ID: 26249241
    [Abstract] [Full Text] [Related]

  • 4. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.
    J Nucl Med; 2015 Nov 15; 56(11):1674-80. PubMed ID: 26294295
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E.
    Eur J Nucl Med Mol Imaging; 2015 Mar 15; 42(3):377-85. PubMed ID: 25432784
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
    Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ.
    J Nucl Med; 2012 Jun 15; 53(6):864-71. PubMed ID: 22582047
    [Abstract] [Full Text] [Related]

  • 7. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar 15; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 8. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 9. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F.
    J Nucl Med; 2013 Aug 22; 54(8):1244-50. PubMed ID: 23674577
    [Abstract] [Full Text] [Related]

  • 10. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V, Odalovic S, Sobic-Saranovic D, Petrovic M, Stojiljkovic M, Petrovic N, Kozarevic N, Grozdic-Milojevic I, Obradovic V.
    Hell J Nucl Med; 2015 Aug 22; 18(1):35-41. PubMed ID: 25840571
    [Abstract] [Full Text] [Related]

  • 11. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
    Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH.
    Eur J Nucl Med Mol Imaging; 2014 Mar 22; 41(3):438-45. PubMed ID: 24196918
    [Abstract] [Full Text] [Related]

  • 12. Impact of (18)F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study.
    Ryu IS, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.
    Eur J Cancer; 2016 Aug 22; 63():88-96. PubMed ID: 27288873
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, Geatti O, Castello A, Laghai I, Popescu CE, Dolci C, Crivellaro C, Seghezzi S, Kirienko M, De Biasi V, Cocciolillo F, Quartuccio N, Young AIMN Working Group.
    Eur J Nucl Med Mol Imaging; 2016 Mar 22; 43(3):404-13. PubMed ID: 26381775
    [Abstract] [Full Text] [Related]

  • 14. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M.
    Eur J Nucl Med Mol Imaging; 2016 Oct 22; 43(11):1937-44. PubMed ID: 27129866
    [Abstract] [Full Text] [Related]

  • 15. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL.
    Eur J Radiol; 2014 Oct 22; 83(10):1925-33. PubMed ID: 24985086
    [Abstract] [Full Text] [Related]

  • 16. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun 22; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 17. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
    Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, Matthews JP, Ball DL.
    J Nucl Med; 2001 Nov 22; 42(11):1596-604. PubMed ID: 11696627
    [Abstract] [Full Text] [Related]

  • 18. (18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?
    Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J, Wasgindt S, Suetterlin M, Schoenberg SO, Sutton EJ, Wasser K.
    Eur Radiol; 2015 Aug 22; 25(8):2460-9. PubMed ID: 25680729
    [Abstract] [Full Text] [Related]

  • 19. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, Evangelista L.
    Eur J Nucl Med Mol Imaging; 2016 Mar 22; 43(3):464-73. PubMed ID: 26268680
    [Abstract] [Full Text] [Related]

  • 20. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S.
    BJU Int; 2013 Oct 22; 112(6):729-34. PubMed ID: 23790129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.